Home » Phase III Trial Shows Crizotinib Superior to Single-Agent Chemotherapy for ALK-Positive Lung Cancer
Phase III Trial Shows Crizotinib Superior to Single-Agent Chemotherapy for ALK-Positive Lung Cancer
The results of a new Phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said.
Medical Xpress
Medical Xpress
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May